ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

被引：217
|
作者：
Cang, Shundong [1 ]
Iragavarapu, Chaitanya [2 ,3 ]
Savooji, John [2 ,3 ]
Song, Yongping [4 ,5 ]
Liu, Delong [4 ,5 ]
机构：
[1] Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou 450052, Peoples R China
[2] Westchester Cty Med Ctr, Dept Med, Valhalla, NY 10595 USA
[3] New York Med Coll, Valhalla, NY 10595 USA
[4] Zhengzhou Univ, Henan Canc Hosp, Zhengzhou 450052, Peoples R China
[5] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450052, Peoples R China
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2015年 / 8卷
关键词：
CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; IN-VIVO EFFICACY; BISPECIFIC ANTI-CD30/CD16A ANTIBODY; ACUTE MYELOID-LEUKEMIA; BH3 MIMETIC ABT-263; FAMILY PROTEINS; CELL-DEATH; HEMATOLOGICAL MALIGNANCIES; NUCLEAR EXPORT;
D O I：
10.1186/s13045-015-0224-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 ( venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins.
引用
收藏
页数：8
相关论文
共 50 条
  • [31] Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models
    Cai, Tianyu
    Kuruvilla, Vinitha Mary
    Lin, Xiaoyu
    Uziel, Tamar
    Lu, Xin
    Zhang, Lu
    Huang, Xiaoli
    Zhang, Qi
    Cavazos, Antonio
    Han, Lina
    Shen, Yu
    Konopleva, Marina Y.
    BLOOD, 2019, 134
  • [32] Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
    Pan, Rongqing
    Hogdal, Leah J.
    Benito, Juliana M.
    Bucci, Donna
    Han, Lina
    Borthakur, Gautam
    Cortes, Jorge
    DeAngelo, Daniel J.
    Debose, LaKeisha
    Mu, Hong
    Doehner, Hartmut
    Gaidzik, Verena I.
    Galinsky, Ilene
    Golfman, Leonard S.
    Haferlach, Torsten
    Harutyunyan, Karine G.
    Hu, Jianhua
    Leverson, Joel D.
    Marcucci, Guido
    Mueschen, Markus
    Newman, Rachel
    Park, Eugene
    Ruvolo, Peter P.
    Ruvolo, Vivian
    Ryan, Jeremy
    Schindela, Sonja
    Zweidler-McKay, Patrick
    Stone, Richard M.
    Kantarjian, Hagop
    Andreeff, Michael
    Konopleva, Marina
    Letai, Anthony G.
    CANCER DISCOVERY, 2014, 4 (03) : 362 - 375
  • [33] Combined Targeting of Mcl-1 With TG02 and Bcl-2 With ABT-199/ABT-737 for Treatment of Hematologic Malignancies
    Burrows, Francis
    Yu, Ning
    Abdul-Aziz, Amina
    Hitosugi, Sadae
    Seedhouse, Claire
    Russell, Nigel
    Boise, Lawrence H.
    Pallis, Monica
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S152 - S152
  • [34] Evaluation of the Bcl-2 inhibitor ABT-199 in xenograft models of acute lymphoblastic leukemia by the pediatric preclinical testing program
    Suryani, Santi
    Evans, Kathryn
    Richmond, Jennifer
    Robbins, Alissa
    Bracken, Lauryn
    Kurmasheva, Raushan
    Houghton, Peter J.
    Smith, Malcolm A.
    Lock, Richard B.
    CANCER RESEARCH, 2015, 75
  • [35] BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis
    Heinicke, Ulrike
    Haydn, Tinka
    Kehr, Sarah
    Vogler, Meike
    Fulda, Simone
    ONCOGENE, 2018, 37 (39) : 5325 - 5339
  • [36] Studying BCL-2 dependence using BH3 profiling in a phase 2 clinical trial of ABT-199 in acute myeloid leukemia.
    Hogdal, Leah
    Chyla, Brenda
    McKeegan, Evelyn
    Leverson, Joel
    Potluri, Jalaja
    Humerickhouse, Rod
    Mack, Mabry
    DeAngelo, Daniel
    Galinsky, Ilene
    Stone, Richard
    Letai, Anthony
    CLINICAL CANCER RESEARCH, 2015, 21
  • [37] ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia
    Peirs, Sofie
    Matthijssens, Filip
    Goossens, Steven
    Van de Walle, Inge
    Ruggero, Katia
    de Bock, Charles E.
    Degryse, Sandrine
    Cante-Barrett, Kirsten
    Briot, Delphine
    Clappier, Emmanuelle
    Lammens, Tim
    De Moerloose, Barbara
    Benoit, Yves
    Poppe, Bruce
    Meijerink, Jules P.
    Cools, Jan
    Soulier, Jean
    Rabbitts, Terence H.
    Taghon, Tom
    Speleman, Frank
    Van Vlierberghe, Pieter
    BLOOD, 2014, 124 (25) : 3738 - 3747
  • [38] BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis
    Ulrike Heinicke
    Tinka Haydn
    Sarah Kehr
    Meike Vogler
    Simone Fulda
    Oncogene, 2018, 37 : 5325 - 5339
  • [39] Lymphocyte depletion, recovery and efficacy in NZBWF1 lupus mice following continuous or intermittent dosing regimen of Venetoclax (ABT-199), a potent and selective BCL-2 Inhibitor
    Wang, L.
    Perper, S.
    Black, K.
    Mario, R.
    Graff, C.
    Hartman, D.
    Souers, A.
    Elmore, S.
    Olson, L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (03) : S33 - S33
  • [40] Lymphocyte Depletion, Recovery and Efficacy in NZBWF1 Lupus Mice Following Continuous or Intermittent Dosing Regimen of Venetoclax (ABT-199), a Potent and Selective BCL-2 Inhibitor
    Wang, Li Chun
    Perper, Stuart
    Black, Kimberly
    Mario, Regina
    Graff, Candace
    Hartman, Dawna
    Souers, Andrew
    Elmore, Steven
    Olson, Lisa
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
12345